Varian ag moneyhouse2/11/2024 Statements concerning Varian's future orders and the anticipated impact of the COVID-19 pandemic on Varian's business and any statements using the terms "could," "believe," "expect," "promising," "outlook," "should," "well-positioned," "will" or similar statements are forward-looking statements that involve risks and uncertainties that could cause Varian's actual results to differ materially from those anticipated. For more information, visit and follow on Twitter.įorward-Looking Statements Except for historical information, this communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Because, for cancer patients everywhere, their fight is our fight. Our 10,000 employees across 70 locations keep the patient and our clinical partners at the center of our thinking as we power new victories in cancer care. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care. ![]() For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. Securities and Exchange Commission.Ībout Varian At Varian, we envision a world without fear of cancer. The final vote results will be filed in a Form 8-K with the U.S. The transaction is expected to close in the first half of calendar year 2021, subject to other regulatory approvals and customary closing conditions. Varian continues to work toward completing the transaction and remains focused on supporting customers and their patients. We look forward to securing the remaining regulatory approvals and closing the transaction." "This vote brings us closer not only toward completing this transformative combination, but also toward realizing our vision of a world without fear of cancer. "The overwhelming support our stockholders have expressed for this combination reflects the compelling value and important opportunity to shape the future of healthcare we see with Siemens Healthineers," said Dow Wilson, Chief Executive Officer. Varian stockholders voted overwhelmingly in favor of the transaction. 15, 2020 /PRNewswire/ - Varian (NYSE: VAR) today announced that its stockholders have voted to approve the previously announced pending combination with Siemens Healthineers AG (Frankfurt: SHL) at a special meeting.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |